Survival of Patients With Colorectal Cancer in a Cancer Center

Abstract

BACKGROUND: Hospital-based studies recently have shown increases in colorectal cancer survival, and better survival for women, young people, and patients diagnosed at an early disease stage. OBJECTIVE: To describe the overall survival and analyze the prognostic factors of patients treated for colorectal cancer at an oncology center. METHODS: The analysis included patients diagnosed with colon and rectal adenocarcinoma between 2000 and 2013 and identified in the Hospital Cancer Registry at A.C.Camargo Cancer Center. Overall 5-year survival was estimated using the Kaplan-Meier method, and prognostic factors were evaluated in a Cox regression model. Hazard ratios (HR) are reported with 95% confidence intervals (CI). RESULTS: Of 2,279 colorectal cancer cases analyzed, 58.4% were in the colon. The 5-year overall survival rate for colorectal cancer patients was 63.5% (65.6% and 60.6% for colonic and rectal malignancies, respectively). The risk of death was elevated for patients in the 50-74-year (HR=1.24, 95%CI =1.02-1.51) and ≥75-year (HR=3.02, 95%CI =2.42-3.78) age groups, for patients with rectal cancer (HR=1.37, 95%CI =1.11-1.69) and for those whose treatment was started >60 days after diagnosis (HR=1.22, 95%CI =1.04-1.43). The risk decreased for patients diagnosed in recent time periods (2005-2009 HR=0.76, 95%CI =0.63-0.91; 2010-2013 HR=0.69, 95%CI =0.57-0.83). CONCLUSION: Better survival of patients with colorectal cancer improves with early stage and started treatment within 60 days of diagnosis. Age over 70 years old was an independent factor predictive of a poor prognosis. The overall survival increased to all patients treated in the period 2000-2004 to 2010-2013.

PIK3C3 Inhibition Promotes Sensitivity to Colon Cancer Therapy by Inhibiting Cancer Stem Cells

“…As per recent estimates, approximately a million new colon cancer cases are reported worldwide every year, and about half of these patients die from the disease [ 2 ]. The five-year survival for CRC patients depends largely on the disease stage as it ranges from 90% for patients with localized disease (stage I) to ~10% when the tumor becomes distant and invasive, and spreads to distant organs (stage IV) [ 3 , 4 ]. The basis of the advanced CRC treatment consists primarily of chemotherapy; however, drug resistance remains a major hurdle [ 5 ].…”

The Interaction Between N6-Methyladenosine Modification and Non-Coding RNAs in Gastrointestinal Tract Cancers

“…Colorectal cancer (CRC) is one of the most common cancers of the digestive system, with the third highest incidence (10.0%) in the world, behind breast cancer (11.7%) and lung cancer (11.4%), and the second highest mortality (9.4%) in the world, only after lung cancer (18%) (106). Although traditional surgery combined with radiotherapy and chemotherapy has greatly improved the poor prognosis of colorectal cancer in recent years, the 5-year survival rate of colorectal cancer is still only 63.5%, and postoperative recurrence and liver metastasis of colorectal cancer are the main reasons for poor prognosis of patients with colorectal cancer (107,108). Therefore, the exploration of the pathogenesis of colorectal cancer has a very important strategic significance.…”

Antiangiogenic Drug-Induced Proteinuria as a Prognostic Factor in Metastatic Colorectal Cancer

“…Colorectal cancer (CRC) has an increased incidence in both men and women [ 1 ]. If diagnosed at an early stage, it is associated with a good prognosis [ 2 ]. However, 20–25% of patients already have metastases at the time of diagnosis and about half of those diagnosed at an early stage will eventually develop metastatic disease [ 3 ].…”